Does margetuximab target the HER2 protein?

Margetuximab (margetuximab-cmkb) is indeed a monoclonal antibody targeting the HER2 protein, specifically used to treat HER2-positive breast cancer and other HER2-expressing tumors. HER2 protein is a receptor tyrosine kinase located on the cell membrane and belongs to the human epidermal growth factor receptor (EGFR) family. Its overexpression or gene amplification is closely related to the occurrence and development of various malignant tumors, especially in breast cancer and gastric cancer. HER2-positive tumors usually exhibit strong invasiveness and poor prognosis, making them important targets for precision therapy.

Margetuximab is similar to traditional trastuzumab in that it works by specifically binding to the external domain of the HER2 protein. However, margetuximab has been engineered in the Fc region to enhance its ability to bind to immune cell Fcγ receptors. This Fc engineering technology enables margituximab to more effectively activate the antibody-dependent cytotoxicity (ADCC) response and promote the immune system's clearance of tumor cells. In contrast, the ADCC activity of ordinary anti-HER2 antibodies is weak, and the improvement of margetuximab helps to improve the efficacy, especially in those patients who are resistant to traditional HER2 antibodies and show better clinical effects.

In addition, margituximab inhibits the proliferation and survival of tumor cells by blockingHER2-mediated signaling. It can prevent the dimerization of HER2 with other receptors and block downstream tumor-promoting signaling pathways, thereby slowing down tumor growth. This dual mechanism, direct inhibition of tumor signaling and activation of immune effects, provides the scientific basis for its therapeutic advantages.

To sum up, margituximab is an innovative antibody drug that clearly targetsHER2 protein. Through its unique Fc engineering, it improves the immune effector function and enhances anti-tumor activity. It is an important breakthrough in the field of HER2-positive tumor treatment and is especially suitable for drug-resistant or refractory patients.

Reference materials:https://www.margenza.com/